**Appendix Table E7. Baseline characteristics of a mixed patient population of patients with ischemic heart, cerebrovascular and peripheral vascular disease in a single study assessing the predictive ability of LTA**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Demographics**  **Total N Enrolled**  **Race (% by group)**  **Male (%)**  **Age\*** | **Vascular disease history**  **Previous CAD (%)**  **Previous heart failure(%)**  **Previous TIA/stroke(%)**  **History of PCI or CABG(%):**  **Stable angina(%)**  **Unstable angina(%)**  **Previous PAD(%)**  **History of MI(%)**  **STEMI/non-STEMI(%)** | **Vascular risk factors**  **Dyslipidemia (%)**  **Smokers (%)**  **BP(mmHg diastolic/systolic**  **HTN (%)**  **Diabetes (%)** | **Prior medications**  **(pre-study)**  **Vitamin K antagonist(%)**  **Clopidogrel(%)**  **Aspirin(%)**  **PPI(%)** | **Procedural data**  **Stent implantation(%)**  **Type of stent(%)**  **Multi-or single vessel(%)** | **Current indication for clopidogrel treatment** | **Current antiplatelet regimen** | **Co-medication** |
| Reny, 2012  22615340  France and Switzerland  ADRIE | 771  NR  81  62.9 | 66  NR  13  NR  NR  NR  21  NR  NR | 36  75  NR  57  22 | NR  99  85.5  29 | NR  NR  NR | patients with symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease) | non–enteric-coated aspirin and/or clopidogrel | NR |

\*Mean (standard deviation), unless otherwise stated.